Skip to main content

Table 1 Training and testing sets of clinical parameters and semantic features of ultrasound

From: Ultrasound-based deep learning radiomics model for differentiating benign, borderline, and malignant ovarian tumours: a multi-class classification exploratory study

 

Training set (n = 680)

 

Testing set (n = 169)

Benign tumour(n = 440)

BOTs(n = 44)

Malignant tumour(n = 196)

P

 

Benign tumour(n = 109)

BOTs(n = 11)

Malignant tumour(n = 49)

P

age (y)

37.07 ± 12.38

42.16 ± 13.71

49.63 ± 13.59

< 0.001*

 

38.70 ± 14.13

39.64 ± 14.66

48.47 ± 10.41

< 0.001*

Height (m)

1.58 ± 0.06

1.58 ± 0.058

1.56 ± 0.06

< 0.001*

 

1.57 ± 0.06

1.58 ± 0.03

1.56 ± 0.04

0.110

Weight (kg)

54.67 ± 9.54

56.51 ± 8.49

55.16 ± 9.01

0.468

 

55.85 ± 9.25

55.11 ± 11.13

54.68 ± 9.52

0.467

BMI

21.95 ± 3.56

22.68 ± 3.25

22.65 ± 3.29

0.014*

 

22.53 ± 3.58

22.12 ± 3.97

22.46 ± 3.73

0.882

RBC_count (1012/L)

4.55 ± 0.53

4.46 ± 0.41

4.36 ± 0.57

< 0.001*

 

4.31 ± 0.55

4.41 ± 0.55

4.30 ± 0.54

0.975

WBC_count (109/L)

7.03 ± 2.00

6.80 ± 2.20

7.79 ± 2.58

< 0.001*

 

7.26 ± 2.77

6.20 ± 0.94

7.11 ± 1.74

0.623

Neutrophil_count (109/L)

4.18 ± 1.788

4.31 ± 2.16

5.22 ± 2.44

< 0.001*

 

4.52 ± 2.62

3.18 ± 0.89

4.72 ± 1.89

0.780

Lymphocyte_count (109/L)

2.12 ± 0.62

1.87 ± 0.63

1.78 ± 0.74

< 0.001*

 

2.06 ± 0.70

2.32 ± 0.74

2.03 ± 1.15

0.906

Monocyte_count (109/L)

0.63 ± 0.28

0.55 ± 0.25

0.64 ± 0.28

0.852

 

0.49 ± 0.19

0.52 ± 0.15

0.51 ± 0.23

0.564

PLT_count (109/L)

296.91 ± 72.08

275.25 ± 56.68

345.37 ± 115.83

< 0.001*

 

282.19 ± 65.22

275.09 ± 82.76

340.04 ± 89.81

< 0.001*

Hemoglobin(g/L)

124.44 ± 18.09

123.34 ± 14.20

117.22 ± 16.54

< 0.001*

 

119.75 ± 16.99

117.18 ± 21.75

114.90 ± 16.21

0.097

NLR

2.20 ± 1.59

2.91 ± 2.73

3.51 ± 2.43

< 0.001*

 

2.72 ± 3.17

1.56 ± 0.75

2.78 ± 1.91

0.991

PLR

154.04 ± 83.09

168.43 ± 94.34

228.71 ± 137.61

< 0.001*

 

151.78 ± 64.23

130.95 ± 53.74

200.41 ± 118.78

0.002*

LMR

3.82 ± 1.62

3.87 ± 1.63

3.40 ± 2.60

0.016*

 

4.51 ± 1.69

4.72 ± 1.96

4.29 ± 1.76

0.510

dNLR

1.57 ± 1.14

1.76 ± 2.50

5.61 ± 47.72

0.073

 

1.88 ± 1.66

1.15 ± 0.51

1.99 ± 1.53

0.799

SII

663.44 ± 534.53

807.60 ± 843.56

1258.88 ± 1026.20

< 0.001*

 

752.95 ± 916.38

430.17 ± 211.21

969.97 ± 779.50

0.190

Menopausal_state, n (%)

   

< 0.001*

    

< 0.001*

Premenopausal

383(87.05%)

28(63.64%)

102(52.04%)

  

90(82.57%)

9(81.82%)

25(51.02%)

 

Menopause

57(12.95%)

16(36.36%)

94(47.96%)

  

19(17.43%)

2(18.18%)

24(48.98%)

 

Tumour_diameter (mm), n (%)

   

< 0.001*

    

0.001*

≤ 50

68(15.45%)

6(13.64%)

12(6.12%)

  

21(19.27%)

1(9.09%)

1(2.04%)

 

50–100

293(66.59%)

18(40.91%)

79(40.31%)

  

59(54.13%)

5(45.45%)

20(40.82%)

 

≥ 100

79(17.95%)

20(45.45%)

105(53.57%)

  

29(26.61%)

5(45.45%)

28(57.14%)

 

Mass_characteristicn, n (%)

   

< 0.001*

    

< 0.001*

Cystic

314(71.36%)

18(40.91%)

13(6.63%)

  

79(72.48%)

4(36.36%)

1(2.04%)

 

Cystic-solid mixed

102(23.18%)

21(47.73%)

89(45.41%)

  

23(21.10%)

6(54.55%)

30(61.22%)

 

Solid

24(5.45%)

5(11.36%)

94(47.96%)

  

7(6.42%)

1(9.09%)

18(36.73%)

 

colour_score, n (%)

   

< 0.001*

    

< 0.001*

1

401(91.14%)

8(18.18%)

11(5.61%)

  

83(76.15%)

4(36.36%)

2(4.08%)

 

2

35(7.95%)

24(54.55%)

77(39.29%)

  

21(19.27%)

7(63.64%)

22(44.90%)

 

3

4(0.91%)

10(22.73%)

91(46.43%)

  

4(3.67%)

0

25(51.02%)

 

4

0

2(4.55%)

17(8.67%)

  

1(0.92%)

0

0

 

Ascites, n (%)

   

< 0.001*

    

< 0.001*

No

437(99.32%)

39(88.64%)

138(70.41%)

  

107(98.17%)

11(100.00%)

40(81.63%)

 

Yes

3(0.68%)

5(11.36%)

58(29.59%)

  

2(1.83%)

0

9(18.37%)

 

Tumour_side, n (%)

   

< 0.001*

    

0.072

Unilateral

379(86.14%)

42(95.45%)

124(63.27%)

  

99(90.83%)

9(81.82%)

38(77.55%)

 

Bilateral

61(13.86%)

2(4.55%)

72(36.73%)

  

10(9.17%)

2(18.18%)

11(22.45%)

 

CA125_level (U/ml), n (%)

   

< 0.001*

    

< 0.001*

≤ 35

304(69.09%)

27(61.36%)

46(23.47%)

  

80(73.39%)

6(54.55%)

14(28.57%)

 

>35, ≤ 200

115(26.14%)

11(25.00%)

51(26.02%)

  

26(23.85%)

4(36.36%)

13(26.53%)

 

>200, <500

16(3.64%)

2(4.55%)

34(17.35%)

  

2(1.83%)

0

8(16.33%)

 

≥ 500

5(1.14%)

4(9.09%)

65(33.16%)

  

1(0.92%)

1(9.09%)

14(28.57%)

 
  1. BOTs: borderline ovarian tumours; BMI: body mass index; RBC: red blood cell; WBC: white blood cell; NLR: neutrophil-to-lymphocyte ratios; PLR: platelet-to-lymphocyte ratios; LMR: lymphocyte-to-monocyte ratios; dNLR: derived neutrophil-to-lymphocyte ratios; SII: systemic immune-inflammation index; CA125: carbohydrate antigen 125; *: P<0.05
Back to article page

BMC Medical Imaging

ISSN: 1471-2342

Contact us